Evidence map›Paper›PMID 41157064›Full record

ArticleMolecules (Basel, Switzerland)2025

Design, Characterization, and Hematopoietic Efficacy of a Fluorinated Pyrazolopiperidine Inclusion Complex.

Zhanargul Koshetova, Guldana Daulet, Assel Ten, Raushan Koizhaiganova, Lyailya Baktybayeva, Tolganay Zharkynbek, Alexey Zazybin, Tulegen Seilkhanov, Nurgul Zhumanova, Valery Dembitsky and 1 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhanargul KoshetovaLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.
Guldana DauletDepartment of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, 71 Al-Farabi Ave., Almaty 050040, Kazakhstan.
Assel TenLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.
Raushan KoizhaiganovaLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0009-0009-8846-7919
Lyailya BaktybayevaDepartment of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, 71 Al-Farabi Ave., Almaty 050040, Kazakhstan.
Tolganay ZharkynbekLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0001-8884-5646
Alexey ZazybinSchool of Chemical Engineering, Kazakh-British Technical University, 59 Tole Bi St., Almaty 050000, Kazakhstan.
Tulegen SeilkhanovLaboratory of Engineering Profile NMR Spectroscopy, Sh. Ualikhanov Kokshetau State University, 76 Abai St., Kokshetau 020000, Kazakhstan.ORCID 0000-0003-0079-4755
Nurgul ZhumanovaDepartment of Chemistry, Kazakh National Women's Teacher Training University, 114 K1 Gogol St., Almaty 050000, Kazakhstan.
Valery DembitskyCentre for Applied Research, Innovation and Entrepreneurship, Lethbridge Polytechnic, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada.ORCID 0000-0002-4603-8704
Valentina YuLaboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, 106 Sh. Ualikhanov St., Almaty 050010, Kazakhstan.ORCID 0000-0001-6508-707X

Funding

the Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan grant number AP23484420the Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan program-targeted funding number BR21882220
6 · The paper itself

Abstract

A novel inclusion complex of a fluorinated pyrazolopiperidine derivative (5-benzyl-7-(2-fluorobenzylidene)-2,3-bis(2-fluorophenyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo [4,3-c]pyridine hydrochloride, PP·HCl) with β-cyclodextrin (

Indexed as

Drug DesignHematopoiesisPiperidinesPyrazolesAnimalsbeta-CyclodextrinsCyclophosphamideMiceSolubilitybeta-CyclodextrinsCyclophosphamidePiperidinesPyrazolescomplex β-Cyclodextrin with 5-benzyl-7-(2-fluorobenzylidene)-2,3-bis(2-fluorophenyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridine (PPβCD)cyclophosphamidelymphocytopoietic-stimulating activitymyelopoietic-stimulating activity

Identifiers

PMID41157064
PMCPMC12566042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.